Tong Ren Tang Technologies Co. Ltd. (Tong Ren Tang Tech) announced that its wholly owned subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, has received a Certificate of Registration of Proprietary Chinese Medicine from the Chinese Medicine Council of Hong Kong.

The approval authorizes the sale of Dingzhi Wan【Tong Ren Tang】 in Hong Kong through 29 September 2031 under registration number HKC-18863. Dingzhi Wan is formulated to “supplement qi and nourish the heart, calm and settle the mind” and targets symptoms such as emotional instability, forgetfulness, and vertigo associated with heart-qi deficiency.

Tong Ren Tang Tech has invested approximately HK$0.80 million in research and development for Dingzhi Wan to date. Commercial launch has not yet commenced. Management expects the certification to broaden the Group’s product portfolio and support market expansion, though it does not anticipate any material short-term impact on production, operations, or financial performance.

The company cautions that sales could be affected by policy changes, exchange-rate fluctuations, and competitive conditions in the Hong Kong market. Shareholders and potential investors are advised to exercise prudence when trading the company’s securities.